hATTR amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms).~Patisiran has shown protective effects on the progression of neurological damage.~The effects of Patisiran on the heart remain incompletely understood.~During their therapeutic management, including the prescription of Patisiran, the routine examinations carried out at the inclusion and one year later will allow us to observe the consequences on myocardial activity during the routine consultation after 1 year of treatment.~Examinations are : clinical and biological exams, EKC, echocardiography, cardiac MRI and scintigraphy.~Data at the start of treatment and at 1 year will be collected, especially cardiac function assesment In addition, during these two consultations, a life quality questionnaire and a functional walking test will be carried out specifically for the study.~The aim of this study is to better understand the morphological and functional cardiac consequences in hATTR patients with stage 1 or 2 polyneuropathy with a mixed form treated with Patisiran.
hATTR amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms).~Patisiran has shown protective effects on the progression of neurological damage.~The effects of Patisiran on the heart remain incompletely understood. The aim of this study is to better understand the morphological and functional cardiac consequences in hATTR patients with stage 1 or 2 polyneuropathy with a mixed form treated with Patisiran.